Stanley Black & Decker, Inc. (SWK) Presents at Goldman Sachs Industrials and Materials Conference 2025 Transcript
Stanley Black & Decker (SWK) reported earnings 30 days ago. What's next for the stock?
Stanley Black & Decker, Inc. ( SWK ) Baird 55th Annual Global Industrial Conference November 12, 2025 1:35 PM EST Company Participants Christopher Nelson - President, CEO & Director Conference Call Participants Timothy Wojs - Robert W. Baird & Co. Incorporated, Research Division Presentation Timothy Wojs Robert W.
| - Industry | - Sector | Jody. D Staggs CEO | NASDAQ (NMS) Exchange | 78501P203 CUSIP |
| US Country | 24 Employees | - Last Dividend | 7 Oct 2015 Last Split | 22 Sep 1999 IPO Date |
SWK Holdings Corporation, headquartered in Dallas, Texas, is a specialized financial service and asset management firm operating predominantly within the United States. Initially known as Kana Software, Inc., the company underwent a name change to SWK Holdings Corporation in December 2009. Since its inception in 1996, SWK Holdings has distinguished itself by focusing on the life sciences sector, providing a unique blend of financial solutions and services to a diversified client base. The company functions through two main divisions: Finance Receivables and Pharmaceutical Development, catering to a wide array of needs in the life science community, including biotechnology, medical devices, diagnostics, animal health, and pharmaceuticals.
This segment of SWK Holdings offers tailored financing solutions targeting a broad spectrum of life science companies and inventors. The clientele encompasses entities from the biotechnology, medical device, diagnostics, animal health, and pharmaceutical industries, among others. By providing flexible financing options, SWK Holdings supports the growth and advancement of companies and technologies within these sectors. Additionally, this segment extends non-discretionary investment advisory services to institutional clients, managing accounts specifically geared towards investments in life science finance.
SWK Holdings' Pharmaceutical Development segment delivers wide-ranging services in pharmaceutical development, formulation, and manufacturing. It is notably recognized for the Peptelligence platform, a proprietary oral drug delivery technology that offers innovative formulation solutions. The segment’s capabilities facilitate the development process for clients, from conceptualization to final product creation, encompassing both development services and formulation technologies. Furthermore, SWK Holdings engages in the intellectual property licensing business, leveraging its developments and technologies to establish partnerships and collaborations within the industry.